GlaxoSmithKline plc (NYSE:GSK) – Research analysts at Jefferies Group boosted their FY2017 EPS estimates for GlaxoSmithKline in a research note issued to investors on Tuesday. Jefferies Group analyst J. Holford now expects that the pharmaceutical company will post earnings of $3.06 per share for the year, up from their prior estimate of $2.91. Jefferies Group also issued estimates for GlaxoSmithKline’s FY2018 earnings at $2.90 EPS, FY2019 earnings at $2.98 EPS, FY2020 earnings at $3.26 EPS and FY2021 earnings at $3.53 EPS.

A number of other research firms have also recently issued reports on GSK. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, October 24th. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Investec cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Monday, November 6th. TheStreet upgraded shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a research note on Wednesday, October 25th. Finally, Bank of America cut shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research note on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $38.57.

Shares of GlaxoSmithKline (NYSE GSK) opened at $38.15 on Thursday. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. The stock has a market cap of $94,002.70, a P/E ratio of 31.27, a price-to-earnings-growth ratio of 2.17 and a beta of 0.98. GlaxoSmithKline has a one year low of $34.52 and a one year high of $44.53.

GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 11th. Stockholders of record on Friday, November 10th were paid a $0.5037 dividend. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.28%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date was Thursday, November 9th. GlaxoSmithKline’s payout ratio is presently 167.21%.

In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of GlaxoSmithKline stock in a transaction dated Monday, November 6th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.00% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the company. FinTrust Investment Advisory Services LLC acquired a new stake in shares of GlaxoSmithKline in the third quarter worth $401,000. Private Advisor Group LLC lifted its stake in shares of GlaxoSmithKline by 7.2% in the third quarter. Private Advisor Group LLC now owns 77,976 shares of the pharmaceutical company’s stock worth $3,166,000 after buying an additional 5,212 shares during the last quarter. San Francisco Sentry Investment Group CA lifted its stake in shares of GlaxoSmithKline by 110.3% in the third quarter. San Francisco Sentry Investment Group CA now owns 8,749 shares of the pharmaceutical company’s stock worth $356,000 after buying an additional 4,589 shares during the last quarter. Renaissance Technologies LLC raised its stake in GlaxoSmithKline by 112.1% during the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after purchasing an additional 4,935,900 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in GlaxoSmithKline during the 3rd quarter valued at $1,209,000. Institutional investors and hedge funds own 9.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/18/jefferies-group-equities-analysts-raise-earnings-estimates-for-glaxosmithkline-plc-gsk.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History and Estimates for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.